Takeda ([url="]TSE:4502/NYSE: TAK[/url])announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (N
iHuman Inc. faces significant headwinds as its core business experiences a persistent revenue decline, evidenced by a 6.9% year-over-year contraction in 2025Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 29, 2026 | -$0.05-301.2% vs $0.02 | $26M-24.7% vs $34M |
Q3 2026 Jun 29, 2026 | $0.06 vs — | $27M vs — |
Q2 2026 Mar 16, 2026 | $0.04 vs — | $27M vs — |
Q4 2025 Dec 29, 2025 | $0.06 vs — | $29M vs — |
Takeda ([url="]TSE:4502/NYSE: TAK[/url])announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (N
[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced new interim data from the ALYFTREKÂ (vanzacaftor/tezacaftor/deutivacaftor) 2 to
iHuman (NYSE: IH - Get Free Report) and IMAX (NYSE: IMAX - Get Free Report) are both communication services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Risk and Volatility iHuman has a beta of 0.04,
BEIJING, Sept. 29, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered knowledge and personal growth products, today announced its unaudited financial results for the second quarter ended June 30, 2026.
Benchmark IH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for iHuman Inc. (IH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.80 | $8.19M | 2.28 | -12.49% | 3.18% | 2.54% | 66.53% | |
| $2.40 | $870.59M | -17.13 | 34.99% | -5.03% | -26.92% | — | |
| $10.29 | $1.04M | -0.06 | 89.09% | -13.77% | — | — | |
| $10.17 | $1.87B | 2.54 | 34.21% | 22.13% | 19.01% | — | |
| $53.03 | $8.32B | 16.38 | 15.94% | 8.44% | 11.57% | — | |
| $18.09 | $2.14B | 90.72 | 5.03% | 2.67% | — | — |
iHuman Inc. (IH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when IH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
iHuman Inc. (IH) stock FAQ — growth, dividends, profitability & financials explained
iHuman Inc. (IH) reported $752.5M in revenue over the trailing twelve months. Revenue was $807.0M in fiscal year 2025. That is 512% more than the $131.9M of fiscal year 2018.
iHuman Inc. (IH) revenue fell by 14.8% over the trailing twelve months, compared with the twelve months before.
Yes. iHuman Inc. (IH) earned $24.0M in net income over the trailing twelve months (a 3.2% net margin).
Yes. iHuman Inc. (IH) pays a dividend that yields 66.53% at the current price, a high yield.
iHuman Inc. (IH) had a return on equity (ROE) of 2.5% over the trailing twelve months. That is below the market's typical 10-15%.